CRISPR Therapeutics AG (LTS:0VRQ) Current Accrued Expense : $76.4 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is CRISPR Therapeutics AG Current Accrued Expense?

CRISPR Therapeutics AG's Current Accrued Expense for the quarter that ended in Mar. 2024 was $76.4 Mil.

CRISPR Therapeutics AG's quarterly Current Accrued Expense declined from Sep. 2023 ($66.4 Mil) to Dec. 2023 ($45.3 Mil) but then increased from Dec. 2023 ($45.3 Mil) to Mar. 2024 ($76.4 Mil).

CRISPR Therapeutics AG's annual Current Accrued Expense declined from Dec. 2021 ($91.0 Mil) to Dec. 2022 ($77.7 Mil) and declined from Dec. 2022 ($77.7 Mil) to Dec. 2023 ($45.3 Mil).

CRISPR Therapeutics AG Current Accrued Expense Historical Data

The historical data trend for CRISPR Therapeutics AG's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Current Accrued Expense Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

30.18

53.78

91.00

77.68

45.34

CRISPR Therapeutics AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															85.63	89.84	66.41	45.34	76.43

CRISPR Therapeutics AG Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

CRISPR Therapeutics AG Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (LTS:0VRQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

CRSP:USA CRSP:Mexico

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

CRISPR Therapeutics AG (LTS:0VRQ) Headlines

No Headlines